News | July 13, 2022
Eversana partners with Compai Pharma to expand commercialisation services across APAC
EVERSANA and Compai Pharma will provide medical and commercial resources to healthcare partners
EVERSANA and Compai Pharma will provide medical and commercial resources to healthcare partners
Plant is part of the company's CAD $30 million capital investment in the site
MINYM can be safely used by patients above 9 years of age.
The appointments will add to the well-diversified experience that currently exists on the PPL board.
The combined company will be able to better serve both our global and regional customers with local production
This is the 142nd ANDA (including 8 tentative approvals received) out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products.
The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.
_256_384.jpg){kind=logo}
Meets the growing need for US-based API solubility and bioavailability enhancement services
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
H Clinical is the leader in decentralized clinical trial support and home visits in Latin America
Subscribe To Our Newsletter & Stay Updated
